Identification of Blood Serum Micro-RNAs Associated With Idiopathic and LRRK2 Parkinson's Disease

被引:126
|
作者
Botta-Orfila, Teresa [1 ]
Morato, Xavier [1 ]
Compta, Yaroslau [1 ,2 ]
Jose Lozano, Juan [3 ]
Falgas, Neus [2 ]
Valldeoriola, Francesc [1 ,2 ]
Pont-Sunyer, Claustre [1 ,2 ]
Vilas, Dolores [1 ,2 ]
Mengual, Lourdes [4 ]
Fernandez, Manel [1 ]
Luis Molinuevo, Jose [2 ,5 ]
Antonell, Anna [2 ,5 ]
Jose Marti, Maria [1 ,2 ]
Fernandez-Santiago, Ruben [1 ]
Ezquerra, Mario [1 ]
机构
[1] Hosp Clin Barcelona, Inst Invest Biomed August Pi & Sunyer IDIBAPS, Ctr Invest Enfermedades Neurodegenerat CIBERNED, Lab Neurodegenerat Disorders,Dept Neurol, E-08036 Barcelona, Catalonia, Spain
[2] Univ Barcelona, Hosp Clin Barcelona, Inst Invest Biomed August Pi & Sunyer IDIBAPS, Movement Disorders Unit,Dept Neurol, Barcelona, Catalonia, Spain
[3] CEK, CIBEREHD, Barcelona, Catalonia, Spain
[4] Hosp Clin Barcelona, Inst Invest Biomed August Pi & Sunyer IDIBAPS, Lab & Dept Urol, E-08036 Barcelona, Catalonia, Spain
[5] Hosp Clin Barcelona, Inst Invest Biomed August Pi & Sunyer IDIBAPS, Alzheimers Dis & Other Cognit Disorders Unit, Neurol Serv, E-08036 Barcelona, Catalonia, Spain
关键词
Parkinson's disease; biomarker; blood; miRNAs; CIRCULATING MICRORNA; EXPRESSION ANALYSIS; CLINICAL-DIAGNOSIS; ALZHEIMERS-DISEASE; PROTEIN; BIOMARKERS; SIGNATURES; MUTATIONS; NEURONS; CANCER;
D O I
10.1002/jnr.23377
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Blood-cell-free circulating micro-RNAs (miRNAs) have been proposed as potential accessible biomarkers for neurodegenerative diseases such as Parkinson's disease (PD). Here we analyzed the serum levels of 377 miRNAs in a discovery set of 10 idiopathic Parkinson's disease (IPD) patients, 10 PD patients carriers of the LRRK2 G2019S mutation (LRRK2 PD), and 10 controls by using real-time quantitative PCR-based TaqMan MicroRNA arrays. We detected candidate differentially expressed miRNAs, which were further tested in a first validation set consisting of 20 IPD, 20 LRRK2 PD, and 20 control samples. We found four statistically significant miRNAs that were downregulated in either LRRK2 or IPD (miR-29a, miR-29c, miR-19a, and miR-19b). Subsequently, we validated these findings in a third set of samples consisting of 65 IPD and 65 controls and confirmed the association of downregulated levels of miR-29c, miR-29a, and miR-19b in IPD. Differentially expressed miRNAs are predicted to target genes belonging to pathways related to ECM-receptor interaction, focal adhesion, MAPK, Wnt, mTOR, adipocytokine, and neuron projection. Results from our exploratory study indicate that downregulated levels of specific circulating serum miRNAs are associated with PD and suggest their potential use as noninvasive biomarkers for PD. Future studies should further confirm the association of these miRNAs with PD. (C) 2014 Wiley Periodicals, Inc.
引用
收藏
页码:1071 / 1077
页数:7
相关论文
共 50 条
  • [31] Transcriptome analysis in LRRK2 and idiopathic Parkinson's disease at different glucose levels
    Fernandez-Santiago, Ruben
    Esteve-Codina, Anna
    Fernandez, Manel
    Valldeoriola, Francesc
    Sanchez-Gomez, Almudena
    Munoz, Esteban
    Compta, Yaroslau
    Tolosa, Eduardo
    Ezquerra, Mario
    Marti, Maria J.
    NPJ PARKINSONS DISEASE, 2021, 7 (01)
  • [32] Mitochondrial DNA in CSF distinguishes LRRK2 from idiopathic Parkinson's disease
    Podlesniy, Petar
    Vilas, Dolores
    Taylor, Peggy
    Shaw, Leslie M.
    Tolosa, Eduard
    Trullas, Ramon
    NEUROBIOLOGY OF DISEASE, 2016, 94 : 10 - 17
  • [33] The Multifaceted Role of LRRK2 in Parkinson's Disease
    Ho, Dong Hwan
    Han, Sun Jung
    Son, Ilhong
    BRAIN SCIENCES, 2025, 15 (04)
  • [34] LRRK2 variant associated with Alzheimer's disease
    Zhao, Yi
    Ho, P.
    Yih, Yuen
    Chen, C.
    Lee, W. L.
    Tan, E. K.
    NEUROBIOLOGY OF AGING, 2011, 32 (11) : 1990 - 1993
  • [35] Sex differences in LRRK2 G2019S and idiopathic Parkinson's Disease
    San Luciano, Marta
    Wang, Cuiling
    Ortega, Roberto A.
    Giladi, Nir
    Marder, Karen
    Bressman, Susan
    Saunders-Pullman, Rachel
    ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY, 2017, 4 (11): : 801 - 810
  • [36] Mutations in LRRK2 as a cause of Parkinson's disease
    Giasson, Benoit I.
    Van Deerlin, Vivianna M.
    NEUROSIGNALS, 2008, 16 (01) : 99 - 105
  • [37] LRRK2, lysosome damage, and Parkinson's disease
    Bentley-DeSousa, Amanda
    Clegg, Devin
    Ferguson, Shawn M.
    CURRENT OPINION IN CELL BIOLOGY, 2025, 93
  • [38] Molecular biology changes associated with LRRK2 mutations in Parkinson's disease
    Lu, Yi Wei
    Tan, Eng-King
    JOURNAL OF NEUROSCIENCE RESEARCH, 2008, 86 (09) : 1895 - 1901
  • [39] Phosphorylation of LRRK2 serines 955 and 973 is disrupted by Parkinson's disease mutations and LRRK2 pharmacological inhibition
    Doggett, Elizabeth A.
    Zhao, Jing
    Mork, Christina N.
    Hu, Dongmei
    Nichols, R. Jeremy
    JOURNAL OF NEUROCHEMISTRY, 2012, 120 (01) : 37 - 45
  • [40] Identification of novel variants in LRRK2 gene in patients with Parkinson's disease in Serbian population
    Jankovic, Milena Z.
    Kresojevic, Nikola D.
    Dobricic, Valerija S.
    Markovic, Vladana V.
    Petrovic, Igor N.
    Novakovic, Ivana V.
    Kostic, Vladimir S.
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2015, 353 (1-2) : 59 - 62